Ignite Creation Date:
2025-12-25 @ 12:27 AM
Ignite Modification Date:
2025-12-25 @ 10:32 PM
Study NCT ID:
NCT04455867
Status:
RECRUITING
Last Update Posted:
2023-04-12
First Post:
2020-06-22
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
The Sunnybrook Type 2 Diabetes Study
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D003924', 'term': 'Diabetes Mellitus, Type 2'}, {'id': 'D011236', 'term': 'Prediabetic State'}, {'id': 'D009043', 'term': 'Motor Activity'}], 'ancestors': [{'id': 'D003920', 'term': 'Diabetes Mellitus'}, {'id': 'D044882', 'term': 'Glucose Metabolism Disorders'}, {'id': 'D008659', 'term': 'Metabolic Diseases'}, {'id': 'D009750', 'term': 'Nutritional and Metabolic Diseases'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}, {'id': 'D001519', 'term': 'Behavior'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000553', 'term': 'Ambulatory Care'}], 'ancestors': [{'id': 'D005791', 'term': 'Patient Care'}, {'id': 'D013812', 'term': 'Therapeutics'}, {'id': 'D006296', 'term': 'Health Services'}, {'id': 'D005159', 'term': 'Health Care Facilities Workforce and Services'}]}}, 'protocolSection': {'designModule': {'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'Serum Plasma White blood cells Urine'}, 'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 500}, 'targetDuration': '18 Months', 'patientRegistry': True}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2017-12-21', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-04', 'completionDateStruct': {'date': '2026-12', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2023-04-10', 'studyFirstSubmitDate': '2020-06-22', 'studyFirstSubmitQcDate': '2020-06-30', 'lastUpdatePostDateStruct': {'date': '2023-04-12', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2020-07-02', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-12', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Depressive episode', 'timeFrame': '6 Months', 'description': 'Depressive episodes are identified using a Structured Clinical Interview for the DSM-5 criteria (SCID-5RV).'}, {'measure': 'Neuropsychological function', 'timeFrame': '6 Months', 'description': 'A Z-score computed from a sensitive neuropsychological battery is administered based on the Canadian Stroke Network \\& National Institutes of Neurological Disorders recommendations.'}], 'secondaryOutcomes': [{'measure': 'Depressive symptoms', 'timeFrame': 'Baseline, 3 Month, 6 Month, 18 Month', 'description': 'Depressive symptoms are monitored using the Beck Depression Inventory-II (BDI-II).'}, {'measure': 'Cognitive Status', 'timeFrame': 'Baseline, 3 Month, 6 Month, 18 Month', 'description': 'Cognitive status is monitored using the Montreal Cognitive Assessment (MoCA).'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Mood', 'Cognition', 'Brain Imaging', 'Type 2 Diabetes', 'Sleep', 'Exercise'], 'conditions': ['Type 2 Diabetes', 'PreDiabetes']}, 'referencesModule': {'references': [{'pmid': '33503568', 'type': 'DERIVED', 'citation': 'Anita NZ, Forkan N, Kamal R, Nguyen MM, Yu D, Major-Orfao C, Wong SK, Lanctot KL, Herrmann N, Oh PI, Shah BR, Gilbert J, Assal A, Halperin IJ, Pedersen TL, Taha AY, Swardfager W. Serum soluble epoxide hydrolase related oxylipins and major depression in patients with type 2 diabetes. Psychoneuroendocrinology. 2021 Apr;126:105149. doi: 10.1016/j.psyneuen.2021.105149. Epub 2021 Jan 19.'}]}, 'descriptionModule': {'briefSummary': 'The Sunnybrook Type 2 Diabetes Study (S2DS) is a prospective observational study of people with prediabetes or Type 2 Diabetes Mellitus (T2DM), that aims to understand the aetiologies, manifestations, and clinical consequences of mood and cognitive complications. The study recruits from the services at Sunnybrook Health Sciences Centre and from the neighbouring University Health Network Toronto Rehabilitation Institute Cardiac Rehabilitation Program.', 'detailedDescription': 'The S2DS is a prospective observational study of people with prediabetes or T2DM recruited from Sunnybrook Health Sciences Centre and the neighbouring University Health Network Toronto Rehabilitation Institute Cardiac Rehabilitation Program. Participants recruited from Sunnybrook are receiving care from services there (e.g. Family Medicine, Endocrinology, and the Sunnybrook Diabetes Education Centre). Participants recruited from the Toronto Rehab are undertaking a 6-month stepped hybrid (home and clinic based) aerobic plus resistance exercise intervention as part of a program at that site (e.g. the Diabetes, Exercise, and Healthy Lifestyle Program).\n\nStudy assessments are conducted at baseline, 3 months, 6 months and 18 months. Main outcomes include cognitive performance, assessed using a detailed neurocognitive battery, and mood symptoms assessed via research criteria for a depressive episode and self-report instruments. Other lifestyle factors are also examined, including physical activity, sleep quality, diet, and subjective stress. Diabetes complications and characteristics are monitored, as are all concomitant medications and supplements. With permission, participant data are linked prospectively to public health records to ascertain long-term outcomes and health services utilization.\n\nThe cohort is characterized using biological, neuroimaging and biometric measures. Fasting morning blood and urine samples are taken at each assessment. Serum, plasma, whole blood, and white blood cells are bio-banked for biochemical, genetic and other analyses. The MRI study includes a 1.5 hr MRI scan at 3.0 T. Sequences performed include structural imaging (T1, T2, DTI and FLAIR) and resting state functional MRI. Two optional sub-studies are offered: a cerebrovascular reactivity MRI protocol, and a sleep quality and apnea protocol (baseline, 6 month and 18 month visits). The sleep study uses an overnight wearable sleep monitor.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'PROBABILITY_SAMPLE', 'studyPopulation': 'The study population consists of individuals with prediabetes or T2DM who are receiving care from an outpatient service at Sunnybrook Health Sciences Centre, or as part of the Diabetes and Healthy Lifestyle Program at the University Health Network Toronto Rehabilitation Institute Cardiac Rehabilitation Program.', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Have at least one of the following: high HbA1c, impaired fasting glucose (IFG), impaired glucose tolerance (IGT), but not yet diagnosed with Type 2 diabetes or have a diagnosis of Type 2 diabetes.\n* Be able to communicate in English\n* Be 18 years of age or older\n\nExclusion Criteria:\n\n* Pregnancy\n* Inability to give informed consent\n* Current cancer diagnosis\n* Have a prior diagnosis of bipolar disorder or schizophrenia.\n* Have a prior diagnosis of a neurological and/or neurodegenerative disorder.\n* Have a current substance use disorder or a previous substance use disorder diagnosed within the last 5 years (excluding nicotine)\n* Poor score on the Mini Mental State Examination (MMSE)\n\nExclusion criteria (Brain Imaging Sub-Study):\n\n* Contraindications to SHSC's MRI safety protocol.\n* Participants that do not meet the inclusion/exclusion criteria of the main study.\n\nExclusion criteria for (Brain Imaging Sub-Study - CVR procedure):\n\n* Use of medical equipment that would interfere with the placement of the CVR mask.\n* Significant pulmonary disease (e.g. asthma, pulmonary fibrosis, emphysema, chronic obstructive pulmonary disease, pulmonary vascular disease, pleural disorders, pneumonia)\n* Participants that do not meet the criteria for the MRI sub-study.\n\nExclusion criteria (Sleep Quality and Apnea Sub-Study):\n\n* Participants that have a medical device that would interfere with placement of portable sleep monitor equipment i.e. Participant requires O2 therapy and uses nasal prongs\n* Participants that have a condition that may compromise accuracy of the HSAT results i.e. moderate-severe pulmonary disease or congestive heart failure\n* Participants that do not meet the inclusion/exclusion criteria of the main study"}, 'identificationModule': {'nctId': 'NCT04455867', 'acronym': 'S2DS', 'briefTitle': 'The Sunnybrook Type 2 Diabetes Study', 'organization': {'class': 'OTHER', 'fullName': 'Sunnybrook Health Sciences Centre'}, 'officialTitle': 'The Sunnybrook Type 2 Diabetes Study', 'orgStudyIdInfo': {'id': '422-2015'}, 'secondaryIdInfos': [{'id': '0939', 'type': 'REGISTRY', 'domain': 'Clinical Trials Ontario'}]}, 'armsInterventionsModule': {'armGroups': [{'label': 'UHN Toronto Rehab', 'description': "Participants with prediabetes of T2DM undertaking a 6-month stepped hybrid (home and clinic based) aerobic plus resistance exercise intervention as per the site's standard protocol (Diabetes Exercise and Healthy Lifestyle Program).", 'interventionNames': ['Behavioral: Diabetes Exercise and Healthy Lifestyle Program']}, {'label': 'Sunnybrook Health Sciences Centre', 'description': 'Participants with prediabetes or T2DM receiving care from an outpatient service at Sunnybrook Health Sciences Centre.', 'interventionNames': ['Other: Outpatient care']}], 'interventions': [{'name': 'Diabetes Exercise and Healthy Lifestyle Program', 'type': 'BEHAVIORAL', 'description': 'The program combines exercise, education and healthy lifestyle behaviour changes. Participants will begin the program with a cardiopulmonary exercise assessment. Then the team will create a personalized program of exercise based on functional abilities and personal goals. Participants will attend 1 supervised exercise class a week, which includes a warm-up and stretching routine, aerobic exercise (walking, stationary cycling or elliptical machine), resistance training and an educational session. This program also offers peer-to-peer support and encourages participants to carry out their own exercise program at home 4 more times per week and to keep a weekly exercise diary to help them with their progress.', 'armGroupLabels': ['UHN Toronto Rehab']}, {'name': 'Outpatient care', 'type': 'OTHER', 'description': 'Participants receive usual care from outpatient services, which may include Endocrinology, Family Medicine, or Diabetes Education', 'armGroupLabels': ['Sunnybrook Health Sciences Centre']}]}, 'contactsLocationsModule': {'locations': [{'zip': 'M4N 3M5', 'city': 'Toronto', 'state': 'Ontario', 'status': 'RECRUITING', 'country': 'Canada', 'contacts': [{'name': 'Walter Swardfager, PhD', 'role': 'CONTACT', 'email': 'w.swardfager@utoronto.ca', 'phone': '416-480-6100'}, {'name': 'Chelsi Major-Orfao, MEd', 'role': 'CONTACT', 'email': 'chelsi.major-orfao@sri.utoronto.ca', 'phone': '416-480-6100', 'phoneExt': '85404'}, {'name': 'Walter Swardfager, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Paul I Oh, MD', 'role': 'PRINCIPAL_INVESTIGATOR'}, {'name': 'Krista L Lanctot, PhD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Baiju R Shah, MD, PhD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Jane Mitchell, PhD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Nathan Herrmann, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Sandra E Black, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Pearl Yang, MD, PhD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Bradley J MacIntosh, PhD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Alexander Kiss, PhD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Mark I Boulos, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Jaan Reitav, PhD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Jeremy Gilbert, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Ilana J Halperin, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Angela Assal, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Andrew Lim, MD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Jennifer S Rabin, PhD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Maged Goubran, PhD', 'role': 'SUB_INVESTIGATOR'}, {'name': 'Ana C Andreazza, PhD', 'role': 'SUB_INVESTIGATOR'}], 'facility': 'Sunnybrook Research Institute', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}], 'centralContacts': [{'name': 'Walter Swardfager, PhD', 'role': 'CONTACT', 'email': 'w.swardfager@utoronto.ca', 'phone': '416-480-6100', 'phoneExt': '85409'}, {'name': 'Chelsi Major-Orfao, MEd', 'role': 'CONTACT', 'email': 'chelsi.major-orfao@sri.utoronto.ca', 'phone': '416-480-6100', 'phoneExt': '85404'}], 'overallOfficials': [{'name': 'Walter Swardfager, PhD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Sunnybrook Research Institute'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Sunnybrook Health Sciences Centre', 'class': 'OTHER'}, 'collaborators': [{'name': 'University Health Network, Toronto', 'class': 'OTHER'}, {'name': 'University of Toronto', 'class': 'OTHER'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Principal Investigator', 'investigatorFullName': 'Walter Swardfager', 'investigatorAffiliation': 'Sunnybrook Health Sciences Centre'}}}}